glioblastoma and brain cancers

DESCRIPTION

Glioblastoma is the most frequent primary brain tumor in adults, representing a highly heterogeneous group of neoplasms that are among the most aggressive and challenging cancers to treat. An improved understanding of the molecular pathways has led to the development of various biomarkers and the evaluation of several agents specifically targeting tumor cells and the tumor microenvironment. However, while occasional targeted therapy responses have been documented in patients, to date no targeted therapy has been formally validated as effective in clinical trials. Treatment developments for the glioblastoma are also tested for all brain cancer types.

Sources: Semantic Scholar

Disclaimer

APPROVED TREATMENTS

¹³¹I-chTNT (Vivatuxin) (glioblastoma)

³²P-Colloidal Chromic Phosphate (brain cancer)

¹³¹I-Iobenguane (MIBG) (neuroblastoma)

IN DEVELOPMENT

¹³¹I-TLX-101 (glioblastoma)

¹⁸⁶Re-RNL (glioblastoma)

²²⁵Ac-DOTA-SP (glioblastoma)

¹⁷⁷Lu-DTPA-Omburtamab (brain cancer, medulloblastoma)

¹³¹I-Omburtamab (neuroblastoma)

¹³¹I-Naxitamab (neuroblastoma)

⁶⁷Cu-SARTATE (neuroblastoma, meningioma)

STATISTICS

View statistics

PATIENT ASSOCIATIONS

Europe: CAN CÉ-TU? (BEL), Brainstrust (GBR), The Brain tumour charity (GBR)

North America: American Brain Tumor Association (USA), National Brain Tumor Society (USA), National Brain Tumor Society (USA)

Worldwide: Accelerate Brain Cancer Cure (ABC2), International Brain Tumour Alliance (IBTA), Brain Tumor Foundation

CLINICAL TRIALS

Brain Cancer ¹³¹I based clinical trials

Glioblastoma ¹³¹I based clinical trials

*non-exhaustive list

ABOUT GLIOBLASTOMA

What is Glioblastoma? – Brain Tumour Charity